世界の院内感染症検査市場予測2021年-2026年

◆英語タイトル:Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
◆商品コード:IMA21AP125
◆発行会社(リサーチ会社):IMARC
◆発行日:2021年4月
◆ページ数:105
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,299 ⇒換算¥252,890見積依頼/購入/質問フォーム
Five UserUSD3,399 ⇒換算¥373,890見積依頼/購入/質問フォーム
EnterprisewideUSD4,499 ⇒換算¥494,890見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はIMARC社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
IMARC社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、世界の院内感染症検査市場を調査・分析し、序論、範囲・調査手法、エグゼクティブサマリー、イントロダクション、疾患別分析、地域別分析、競争状況などを掲載しています。
【レポートの概要】

The global hospital-acquired disease testing market reached a value of US$ 7.32 Billion in 2020. Hospital acquired infections (HAIs) or nosocomial infections are diseases that are acquired in hospitals and medical clinics. Nosocomial means, infections or diseases originating in a hospital. A person can get such diseases even in the vicinity of a nursing home, rehabilitation center, hospital or any other clinical surroundings. Most people get HAIs when they are in intensive care units (ICUs) and the emergency rooms (ERs). Generally, the incubation period of these diseases vary between 48 hours to 4 days after the individual gets admitted. A major reason behind the cause of hospital acquired diseases is the lack of proper hygiene in the hospital settings by the internal staff. Another reason can be below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the most commonly occurring nosocomial infections include pneumonia, primary bloodstream infections, urinary tract infections, etc. In many cases, it has also been found that these nosocomial infections are sometimes traced to the patients’ own microbiome. It happens when the protective skin layer comes in contact with possible threats and causes infection to occur, especially after surgical operations.
The market for hospital acquired disease testing is currently exhibiting double digit growth rates. Catalyzed by rising population and modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests. Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization. Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market. Looking forward, IMARC Group expects the global hospital acquired disease testing market to exhibit strong growth during the next five years.

Market Summary:

Based on the indication, the market has been segmented into urinary tract infection, surgical site infection, pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus and others. Urinary tract infection currently represents the biggest segment.
Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
The competitive landscape of the market has also been examined with some of the key players being Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.

This report provides a deep insight into the global hospital-acquired disease testing market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the hospital-acquired disease testing market in any manner.

Key Questions Answered in This Report:

1. What is the market size for the global hospital acquired disease testing market?
2. What is the global hospital acquired disease testing market growth?
3. What are the global hospital acquired disease testing market drivers?
4. What are the key industry trends in the global hospital acquired disease testing market?
5. What is the impact of COVID-19 on the global hospital acquired disease testing market?
6. What is the global hospital acquired disease testing market breakup by indication?
7. What are the major regions in the global hospital acquired disease testing market?
8. Who are the key companies/players in the global hospital acquired disease testing market?

【レポートの目次】

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Hospital Acquired Disease Testing Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Breakup by Indication
5.5 Market Breakup by Region
5.6 Market Forecast
5.7 SWOT Analysis
5.7.1 Overview
5.7.2 Strengths
5.7.3 Weaknesses
5.7.4 Opportunities
5.7.5 Threats
5.8 Value Chain Analysis
5.9 Porters Five Forces Analysis
5.9.1 Overview
5.9.2 Bargaining Power of Buyers
5.9.3 Bargaining Power of Suppliers
5.9.4 Degree of Competition
5.9.5 Threat of New Entrants
5.9.6 Threat of Substitutes
5.10 Price Analysis
6 Market Breakup by Indication
6.1 UTI (Urinary Tract Infection)
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 SSI (Surgical Site Infection)
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Pneumonia
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Bloodstream Infections
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 MRSA (Methicillin-Resistant Staphylococcus Aureus)
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market Trends
6.6.2 Market Forecast
7 Market Breakup by Region
7.1 North America
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Europe
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Asia Pacific
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Middle East and Africa
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Latin America
7.5.1 Market Trends
7.5.2 Market Forecast
8 Competitive Landscape
8.1 Market Structure
8.2 Key Players
8.3 Profiles of Key Players
8.3.1 Abbott Laboratories
8.3.2 Alere, Inc.
8.3.3 Becton, Dickinson and Company
8.3.4 bioMérieux SA
8.3.5 F. Hoffmann-La Roche Ltd.
8.3.6 Hologic, Inc.
8.3.7 QIAGEN
8.3.8 Siemens Healthcare
8.3.9 Diatherix Laboratories, Inc.
8.3.10 Meridian Bioscience, Inc.
8.3.11 Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
8.3.12 Cepheid, Inc.

Figure 1: Global: Hospital Acquired Disease Testing Market: Major Drivers and Challenges
Figure 2: Global: Hospital Acquired Disease Testing Market: Sales Value (in Billion US$), 2015-2020
Figure 3: Global: Hospital Acquired Disease Testing Market: Breakup by Indication (in %), 2020
Figure 4: Global: Hospital Acquired Disease Testing Market: Breakup by Region (in %), 2020
Figure 5: Global: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 6: Global: Hospital Acquired Disease Testing Industry: SWOT Analysis
Figure 7: Global: Hospital Acquired Disease Testing Industry: Porter’s Five Forces Analysis
Figure 8: Global: Hospital Acquired Disease Testing Industry: Porter’s Five Forces Analysis
Figure 9: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market: Sales Value (in Million US$), 2015 & 2020
Figure 10: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 11: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market: Sales Value (in Million US$), 2015 & 2020
Figure 12: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 13: Global: Hospital Acquired Disease Testing (Pneumonia) Market: Sales Value (in Million US$), 2015 & 2020
Figure 14: Global: Hospital Acquired Disease Testing (Pneumonia) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 15: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market: Sales Value (in Million US$), 2015 & 2020
Figure 16: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 17: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market: Sales Value (in Million US$), 2015 & 2020
Figure 18: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 19: Global: Hospital Acquired Disease Testing (Other Indications) Market: Sales Value (in Million US$), 2015 & 2020
Figure 20: Global: Hospital Acquired Disease Testing (Other Indications) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 21: North America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
Figure 22: North America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 23: Europe: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
Figure 24: Europe: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 25: Asia Pacific: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
Figure 26: Asia Pacific: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 27: Middle East and Africa: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
Figure 28: Middle East and Africa: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 29: Latin America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
Figure 30: Latin America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026

Table 1: Global: Hospital Acquired Disease Testing Market: Key Industry Highlights, 2020 and 2026
Table 2: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Indication (in Million US$), 2021-2026
Table 3: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Region (in Million US$), 2021-2026
Table 4: Global: Hospital Acquired Disease Testing Market: Competitive Structure
Table 5: Global: Hospital Acquired Disease Testing Market: Key Players

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の院内感染症検査市場予測2021年-2026年]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆